Recent Advances in the Excipients Used in Modified Release Vaginal Formulations

被引:21
作者
Dedeloudi, Aikaterini [1 ]
Siamidi, Angeliki [1 ]
Pavlou, Panagoula [2 ]
Vlachou, Marilena [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Dept Pharm, Div Pharmaceut Technol, Athens 15784, Greece
[2] Univ West Att, Dept Biomed Sci, Lab Chem Biochem Cosmet Sci, 28 Ag Spyridonos Str, Egaleo 12243, Greece
关键词
novel vaginal excipients; co-polymers; mucoadhesive; bio-adhesive; thermosensitive; vaginal drug delivery; novel vaginal formulations; vaginal films; vaginal nanomedicines; IN-VITRO EVALUATION; DRUG-DELIVERY; PENETRATION ENHANCEMENT; WOMENS PREFERENCES; INTRAVAGINAL RING; TARGETED DELIVERY; CERVICAL-MUCUS; HIV-INFECTION; MICROBICIDE; TENOFOVIR;
D O I
10.3390/ma15010327
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The formulation of an ideal vaginal drug delivery system (DDS), with the requisite properties, with respect to safety, efficacy, patient compliance, aesthetics, harmonization with the regulatory requirements, and cost, requires a meticulous selection of the active ingredients and the excipients used. Novel excipients defined by diversity and multifunctionality are used in order to ameliorate drug delivery attributes. Synthetic and natural polymers are broadly used in pharmaceutical vaginal formulations (solid, semi-solid dosage forms, implantable devices, and nanomedicines) with a promising perspective in improving stability and compatibility issues when administered topically or systemically. Moreover, the use of biopolymers is aiming towards formulating novel bioactive, biocompatible, and biodegradable DDSs with a controllable drug release rate. Overviewing vaginal microenvironment, which is described by variable and perplexed features, a perceptive choice of excipients is essential. This review summarizes the recent advances on the excipients used in modified vaginal drug delivery formulations, in an attempt to aid the formulation scientist in selecting the optimal excipients for the preparation of vaginal products.
引用
收藏
页数:17
相关论文
共 95 条
[31]   Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles [J].
Ham, Anthony S. ;
Cost, Marilyn R. ;
Sassi, Alexandra B. ;
Dezzutti, Charlene S. ;
Rohan, Lisa Cencia .
PHARMACEUTICAL RESEARCH, 2009, 26 (03) :502-511
[32]   Women's preferences for vaginal antimicrobial contraceptives III -: Choice of a formulation, applicator, and packaging [J].
Hardy, E ;
Jiménez, AL ;
de Pádua, KS ;
Zaneveld, LJD .
CONTRACEPTION, 1998, 58 (04) :245-249
[33]   S-protected gellan gum: Decisive approach towards mucoadhesive antimicrobial vaginal films [J].
Jalil, Aamir ;
Asim, Mulazim Hussain ;
Nguyet-Minh Nguyen Le ;
Laffleur, Flavia ;
Matuszczak, Barbara ;
Tribus, Martina ;
Bernkop-Schnurch, Andreas .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 130 :148-157
[34]   Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers [J].
Jespers, Vicky A. ;
Van Roey, Jens M. ;
Beets, Greet I. ;
Buve, Anne M. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 44 (02) :154-158
[35]   Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir [J].
Johnson, Todd J. ;
Gupta, Kavita M. ;
Fabian, Judit ;
Albright, Theodore H. ;
Kiser, Patrick F. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 39 (04) :203-212
[36]  
Kalita B., 2017, ASIAN J PHARM CLIN R, V10, P418, DOI [10.22159/ajpcr.2017.v10i3.16417, DOI 10.22159/AJPCR.2017.V10I3.16417]
[37]  
Kar M, 2019, ADV PHARM PROD DEVL, P29, DOI 10.1016/B978-0-12-817909-3.00002-9
[38]   HUMAN CERVICAL-MUCUS - RESEARCH UPDATE [J].
KATZ, DF .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 165 (06) :1984-1986
[39]   Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers [J].
Khanna, Niharika ;
Dalby, Richard ;
Connor, Alyson ;
Church, Ann ;
Stern, Jennifer ;
Frazer, Neil .
SEXUALLY TRANSMITTED DISEASES, 2008, 35 (06) :577-582
[40]   Phase I/II clinical safety studies of terameprocol vaginal ointment [J].
Khanna, Niharika ;
Dalby, Richard ;
Tan, Ming ;
Arnold, Stephanie ;
Stern, Jennifer ;
Frazer, Neil .
GYNECOLOGIC ONCOLOGY, 2007, 107 (03) :554-562